Phase II and pharmacologic study of topotecan administered as a 21-day continuous infusion to patients with colorectal cancer

Journal of Clinical Oncology

Volumn 14, Issue 9, 1996, Pages 2540-2545

  Creemers, G J ^a   Gerrits, C J ^a   Schellens, J H ^a   Planting, A S ^a   van der Burg, M E ^a   van Beurden, V M ^a   de Boer Dennert, M ^a   Harteveld, M ^a   Loos, W ^a   Hudson, I ^a   Stoter, G ^a   Verweij, J ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; TOPOTECAN;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER INHIBITION; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEADY STATE;

EID: 9544234452     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.9.2540     Document Type: Article

References (24)

1. Köhne-Wömpener CH, Schmoll HL, Harstrick A, et al: Chemotherapeutic strategies in metastatic colorectal cancer: An over-view of current clinical trials. Semin Oncol 19:105-125, 1992
2. Graf W, Påhlman L, Bergström R, et al: The relationship between an objective response to chemotherapy and survival in advanced colorectal cancer. Br J Cancer 70:559-563, 1994
3. Moertel CG: Drug therapy: Chemotherapy for colorectal cancer. N Engl J Med 330:1136-1142, 1994
4. Kingsburry WD, Hertzberg RP, Boehm JC, et al: Chemical synthesis and structure-activtty-relationships related to SK&F 104864, a novel watersoluble analog of camptothecin. Proc Am Soc Cancer Res 30:622, 1989 (abstr)
5. Kingsburry WD, Boehm JC, Jakas DR, et al: Synthesis of watersoluble (aminoalkyl) camptothecin analogues: Inhibition of topoisomerase-I and antitumor activity. J Med Chem 34:98-107, 1991
6. Hsiang YH, Hertzberg R, Hecut S, et al: Camptothecin induces protein-linked DNA breaks via mammilian DNA topisomerase I. J Biol Chem 260:14873-14878, 1985
7. Hsiang YH, Liu LF: Identification of mammilian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722-1726, 1988
8. Giovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase I-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048, 1989
9. Houghton PJ, Cheshire PJ, Myers L, et al: Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin (topotecan) against xenografts derived from adult and childhood tumors. Cancer Chemother Pharmacol 31:229-239, 1992
10. Burris III HA, Hanauske AR, Johnson RK, et al: Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units. J Natl Cancer Inst 84:1816-1820, 1992
11. Hochster H, Liebes L, Speyer J, et al: Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen. J Clin Oncol 12:553-559, 1994
12. National Cancer Institute: Guidelines for reporting of adverse drug reactions. Bethesda, MD, Division of Cancer Treatment, National Cancer Institute, 1988
13. World Health Organization: WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication no. 48. Geneva, Switzerland, World Health Organization, 1979
14. Loos WJ, Stoter G, Verweij J, et al: Sensitive high liquid Chromatographic fluorescence assay for the quantition of topotecan (SKF 104864-A) and the lactone ring-opened product (hydroxy-acid) in human plasma and urine. J Chromatography Biomed Appl 678:309-315, 1996
15. Daniak N, Kreczko S, Hanspal M, et al: DNA topisomerase inhibitors block erythropoiesis and delay hemoglobinization in vitro. J Cell Physiol 138:87-96, 1989
16. Johnson RK, McCabe FL, Faucette LF, et al: SKF 104864, a watersoluble analog of camptothecin with a broad spectrum of activity in preclinical models. Proc Am Assoc Cancer Res 30:623, 1989 (abstr)
17. Creemers GJ, Wanders J, Gamucci T, et al: Topotecan in Colorectal cancer: A phase II study of the EORTC Early Clinical Trials Group. Ann Oncol 6:844-846, 1995
18. Sugarman SM, Ajani JA, Daughertly K, et al: A phase II trial of topotecan (TPT) for treatment of advanced measurable colorectal cancer. Proc Am Soc Clin Oncol 12:686, 1994 (abstr)
19. Shimada Y, Yoshina M, Wakui A, et al: Phase II study of CPT-11, a new camptothecin derivative in metastatic colorectal cancer. J Clin Oncol 11:909-913, 1993
20. Conti JA, Kenemy N, Saltz L, et al: Irinotecan (CPT-11) is an active agent in untreated patients with metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 13:195, 1994 (abstr)
21. Pitot HC, Wender D, O'Connell MJ, et al: A phase II trial of CPT-11 (irinotecan) in patients with metastatic colorectal carcinoma: A North Central Cancer Treatment Group (NCCTG) study. Proc Am Soc Clin Oncol 13:197, 1994 (abstr)
22. Rothenberg ML, Eckardt JR, Burris III HA, et al: Irinotecan (CPT-11) as second-line therapy for patients with 5-FU-refractory colorectal cancer. Proc Am Soc Clin Oncol 13:198, 1994 (abstr)
23. Warmerdam LJC, Creemers GJ, Rodenhuis S, et al: Pharmacokinetics and pharmacodynamics of topotecan administered at a daily times five schedule in phase II clinical trials using a limited sampling procedure. Cancer Chemother Pharmacol 38:254-260, 1996
24. Creemers GJ, Schellens JHM, Beijenen JH, et al: Bioavailability of oral topotecan, a new topoisomerase I inhibitor. Proc Am Soc Clin Oncol 13:132, 1994 (abstr)